Treatment with systemic corticosteroids > mg/day, prednisone or equivalent
Subject with Graft vs. Host Disease (GVHD) who is receiving treatment with systemic glucocorticoids >  mg/day equivalent of prednisone; however, treatment with low dose glucocorticoids (?  mg/day equivalent of prednisone) is permitted
Any immunomodulatory drug therapy, anti-neoplastic hormonal therapy (unless dose has been stable for  months prior to Baseline and will remain stable during the trial), immunosuppressive therapy, corticosteroids > mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin) within  days prior to initiation of study drug.
Any prednisone (or equivalent corticosteroids) use within  weeks of study entry
Subjects receiving immunologically based treatment for any reason, including chronic steroids or prednisone (at dose >  mg/day of prednisone) within  day prior to first study treatment; inhaled or topical steroids or systemic steroids (at dose =<  mg/day of prednisone) is permitted
Treatment with systemic corticosteroids ?  mg/day prednisone or equivalent, for non-lymphoma treatment reasons. For lower acceptable doses, documentation of a stable dose for at least  weeks prior to Day  of Cycle  is required.
Any other concurrent investigational agent or chemotherapy, radiotherapy, immunotherapy, or corticosteroids (prednisone up to  mg/day or its equivalent is permitted for chronic conditions)
Systemic glucocorticoid therapy (prednisone > mg/day orally or equivalent) within the last  weeks prior to first dose, unless tapered and on a stable dose (prednisone ? mg/day orally or equivalent) for at least  week.
Previously untreated; NOTE: this includes any chemotherapy or immunotherapy or RIT; patients who received corticosteroids for diseases other than lymphoma are eligible as long as prednisone dose is =<  mg/day
Systemic corticosteroids greater than the equivalent of  mg of prednisone per day within  weeks of study drug administration are prohibited
Systemic steroids that have not been stabilized to the equivalent of =<  mg/day prednisone prior to the start of the study drugs
Prior treated CNS metastases must be without MRI evidence of recurrence for at least  weeks after treatment; patients must be off immunosuppressive doses of systemic steroids (>=  mg/day prednisone or equivalent) for at least  days prior to study drug administration, and must have returned to neurologic baseline status postoperatively\r\n* The -week period of stability is measured after the completion of the neurologic interventions (ie, surgery and/or radiation)
Immunosuppressive treatments within  weeks prior to embolization, unless prednisone ?  mg or equivalent
Patients that require decadron >  mg/ day or equivalent of steroids.
Patients may be on steroids prior to initiation of treatment, provided that, by cycle  day , steroid use is tapered down to less than or equal to  mg/day of prednisone
The subject is off corticosteroids of >  mg/day prednisone or equivalent.
No concurrent treatment for the CNS disease (e.g. surgery, radiation, corticosteroids > mg prednisone/day or equivalent)
Treatment with systemic corticosteroids (>  mg per day prednisone or equivalent) or other immune suppressive drugs within  weeks
Received a cumulative dose of corticosteroids equivalent to greater than or equal to ( >=)  milligram (mg) of prednisone within the -day period before the first dose of study drug
If patient is currently on prednisone or other corticosteroids for palliation, the dose must be less than or equal to  mg a day or its equivalent dose and it must have been started at least  weeks prior to cycle  day 
Systemic therapy with corticosteroids at > mg/day prednisone or equivalent within  week prior to the first dose of study drug
The following medications are prohibited within  weeks of enrollment and while on study drug:\r\n*  alpha-reductase inhibitors (finasteride, dutasteride)\r\n* Biologic or other agents with anti-tumor activity against prostate cancer (excluding herbal supplements)\r\n* Systemic glucocorticoids greater than the equivalent of  mg per day of prednisone\r\n** Premedication with systemic glucocorticoids greater than the equivalent of  mg per day of prednisone is permitted prior to docetaxel infusions\r\n* Androgens (testosterone, dehydroepiandrosterone [DHEA], etc.)
Subjects who are currently using more than mg/day of prednisone (or an equivalent glucocorticoid exceeding physiologic replacement levels)
Patients who take any immune or bone marrow suppressive agents including any systemic corticosteroid that exceed an equivalent of  mg prednisone per day within  weeks from the study treatment. Inhalation or topical steroids are allowed.
Received a cumulative dose of corticosteroids equivalent to greater than or equal to (>=)  milligram (mg) of prednisone within the -day period before the first dose of study drug
Subject has received a cumulative dose of corticosteroids more than the equivalent of >=  mg of prednisone within the  week period before cycle , day 
No use of systemic steroids greater than the equivalent of  mg of prednisone/prednisolone per day within  weeks prior to enrollment
Patients with treated, non-progressive brain metastases, off high-dose steroids (> mg prednisone or equivalent) for at least  weeks can be enrolled in the trial.
Prednisone dose =<  mg/day and off all other systemic immunosuppressive medications for at least  weeks prior to study entry
Patients may be on steroids prior to initiation of treatment, provided that, by cycle  day , steroid use is tapered down to less than or equal to  mg/day of prednisone
Brain metastases that are clinically unstable (e.g. showing unequivocal growth on imaging, requiring radiation therapy, or steroids >mg of prednisone equivalent) within  weeks of first dose of study drug.
Human immunodeficiency virus (HIV)-positive patients, patients with acquired or congenital immunodeficiency conditions, those on chronic systemic immunosuppressants (requiring >  mg of prednisone or equivalent/day), those with active autoimmune disease are excluded from the study
Chronic use (>  weeks) of corticosteroids (prednisone >=  mg/ hour [hr] equivalent) within  weeks of screening
No prior treatment except a prior limited-field radiotherapy, a short course of glucocorticoids =<  mg daily of prednisone equivalent which must cease prior to day  of cycle , and/or cyclophosphamide for an urgent lymphoma related problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome)
Unstable, symptomatic brain metastases; Note: participants whose symptoms are controlled on a stable dose of corticosteroids (=<  mg prednisone equivalent per day) for at least  weeks will be eligible
At least  weeks from prior therapy to time of start of treatment; prior therapy includes steroids (except prednisone or equivalent - up to  mg per day is allowed)
Patients receiving systemic steroids ? mg/day of prednisone or the equivalent
Receiving corticosteroids >  mg of prednisone per day (or equivalent); Note: the dose should be noted on the medication record each cycle
No autoimmune disease or chronic steroids (dose of >  mg/day prednisone equivalent) or other immunosuppressive medications within  days of randomization (for MSI-H nivolumab group)
Receipt of systemic cancer therapy, immunomodulatory drug therapy, immunosuppressive therapy, or corticosteroids >  mg/day prednisone or equivalent within  days prior to the Baseline Visit or concurrently during the trial.
Patients who are currently receiving chronic (>  days) treatment with corticosteroids at a dose >=  mg of prednisone (or its glucocorticoid equivalent) per day, or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug
Regular treatment with corticosteroids during the  weeks prior to the start of cycle , unless administered for indications other than NHL at a dose equivalent to =<  mg/day prednisone
If receiving corticosteroids, ?  mg/day prednisone or equivalent and unchanged
Receiving corticosteroids above physiological dosing (>  mg per day of prednisone) within  days prior to anti-CD-CAR-transduced T cell administration
Ability to be off prednisone and other immunosuppressive drugs (<  mg/day) for at least  days prior to and while receiving ALT-
Patients on systemic corticosteroids (> mg prednisone per day or equivalent) or other systemic immunosuppressive drugs
Prednisone dose ?  mg/day
Patients receiving systemic steroids ? mg/day of prednisone or the equivalent
Treatment with corticosteroids (? mg per day prednisone or equivalent) or other immune suppressive drugs within the  days prior to the initiation of study drug administration.
Ongoing corticosteroids for indications other than multiple myeloma allowed as long as the dose does not exceed  mg of prednisone per day or equivalent
Chronic use (?  weeks) of corticosteroids (?  mg/ hour equivalent prednisone) within  weeks of Baseline/Cycle  Day  visit.
Patients with a history of severe immune-mediated adverse reactions with ipilimumab: this will be defined as any grade  toxicity requiring treatment with corticosteroids (greater than  mg/day prednisone or equivalent dose) for greater than  weeks
Patients must not be receiving concurrent steroids >  mg prednisone (or equivalent)\n             per day.
Systemic corticosteroids within  weeks, except low dose regimens (prednisone, ? \n             mg/day, or equivalent) which may continue if unchanged
No corticosteroids are permitted, except for maintenance therapy for a non-malignant disease or to prevent treatment-related ofatumumab reactions (maintenance therapy dose must not exceed  mg/day prednisone or equivalent)
Patients must have completed prednisone taper ( mg - . mg) prior to randomization
Prior systemic glucocorticosteroid use for the treatment of non-malignant disorders is permitted; concurrent use after registration on the study should be restricted to the equivalent of prednisone  mg per day
Systemic therapy with corticosteroids at > mg/day prednisone or equivalent within  week prior to the first dose of study drug
Subject received treatment with systemic glucocorticoids greater than the equivalent of  mg per day of prednisone within  weeks prior to day , intended for the treatment of prostate cancer.
Glucocorticoid therapy (prednisone >  mg/day or equivalent) within  days prior to study day
Regular treatment with corticosteroids within the  or  weeks prior to the start of Cycle , unless administered for indications other than non-Hodgkin's lymphoma at a dose equivalent to <  mg/day prednisone/prednisolone
Patients must not be receiving chronic treatment (equivalent of prednisone >  mg/day) with systemic steroids or other immuno-suppressive agent
No prior anti-lymphoma therapy. However, for subjects with bulky disease,systemic symptoms, compressive disease, or rapidly progressing adenopathies, pre-phase treatment with  mg/kg/day prednisone, or equivalent, for a maximum of  days is permitted prior to Cycle  Day - at the discretion of the Investigator. In exceptional cases, if clinically indicated, a higher dose of steroids and/or a slightly longer duration is allowed for the purpose of urgent symptom management, and the subjects is considered eligible. A washout period does not apply. However the fresh core biopsy mentioned above should be performed before starting prednisone.
Chronic use (?  weeks) of corticosteroids (?  mg/ hr equivalent prednisone) within  weeks of Baseline/First Dose.
Received any chemotherapy, immunomodulatory or immunosuppressive therapy, corticosteroids (greater than [>] milligram per day [mg/day] prednisone or equivalent) within  days prior to randomization
Patients receiving concomitant immunosuppressive agents or chronic corticosteroids (? mg of prednisone or equivalent) at the time of first study dose.
Patients who are currently receiving chronic (>  days) treatment with corticosteroids at a dose equal to or more than  mg of prednisone (or its glucocorticoid equivalent) per day, or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug
Subjects taking corticosteroids during the last week prior to study treatment, unless administered at a dose equivalent to <  mg/day prednisone or prednisolone.
Use of prednisone (or equivalent corticosteroid dose) for SM up to  mg/day or its equivalent is allowed, but it cannot have been started during screening; patients who are on prednisone up to  mg/day for medical problems unrelated to SM are also permitted on study
Have received corticosteroids greater than (>)  milligram per day (mg/day) prednisone or equivalent, or growth factor treatment within  weeks prior to study entry
Participants using concomitant corticosteroids are allowed as long as the subject is on the equivalent of  mg/day or less of prednisone and has been on a stable dose for at least two weeks prior to initiating therapy
Ongoing treatment with chronic immunosuppressants (eg, cyclosporine) or systemic steroids >  mg prednisone (or equivalent) QD
No chronic use of systemic steroids greater than the equivalent of  mg of prednisone/prednisolone per day within  weeks prior to enrollment
Use of systemic steroids at an equivalent dose of prednisone  mg/day or higher at randomization
Current treatment with immunosuppressive agents other than prescribed corticosteroids (not more than -mg prednisone equivalent).
Systemic steroids that have not been stabilized to the equivalent of =<  mg/day of prednisone  days prior to the initiation of the trial
Oral corticosteroids >= . mg/day prednisone (or prednisone equivalents)
Patient on corticosteroids within two weeks prior to study entry, except for prednisone < =  mg/day or equivalent for purposes other than treating MCL.
Chronic systemic steroids (> mg/day Prednisone equivalents) or any other immunosuppressive agents
Patients cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy or chronic treatment dose corticosteroids (greater than the equivalent of  mg prednisone per day), within  months of the first vaccination; treatment or salvage radiation therapy must have been completed at least  weeks prior to the first vaccination
Receiving corticosteroids >  mg of prednisone per day (or equivalent)
Any condition requiring chronic use of moderate/high dose steroids (equivalent to  mg QD prednisone).
Chronic use of systemic corticosteroids (i.e., >=  mg/day prednisone or equivalent)
Receipt of systemic corticosteroids within  weeks of study treatment, unless patient has been taking a continuous dose of  mg/day or less of oral prednisone or equivalent for at least  weeks or as part of a CHOP prednisone taper.
Able to be off prednisone or other immunosuppressive medications for at least  days prior to Day  (excluding pre-medications); low dose prednisone (<  mg/day) is allowed if for indication other than graft-versus-host disease (GVHD)
Has, within  weeks prior to Day , received systemic corticosteroids exceeding prednisone  mg per day or equivalent; for other immunosuppressive agents, the exclusionary dose and duration will be determined in consultation with the Medical Monitor.
Concurrent use of other anti-cancer agents or treatments. NOTE: Growth factors and bisphosphonates are allowed as medically indicated. Steroids may be used with an equivalency of up to  mg of Prednisone per day as long as the dose has not been adjusted upwards in past  weeks prior to study registration.
Prior treated CNS metastases must be without MRI evidence of recurrence for at least  weeks after treatment. Patients must be off immunosuppressive doses of systemic steroids (?  mg/day prednisone or equivalent) for at least  days prior to study drug administration, and must have returned to neurologic baseline status postoperatively.  The -week period of stability is measured after the completion of the neurologic interventions (ie, surgery and/or radiation).
On immunosuppressive or other anti-leukemic therapy, excluding patients receiving glucocorticoids for management of circulating blast count or patients on a stable dose (<mg/m/day prednisone or equivalent) of systemic or topical glucocorticoid therapy with ? Grade  GvHD or tapering dose of calcineurin inhibitor
Glucocorticoid therapy (prednisone >  mg/day or equivalent within  days of first dose)
Treatment with oral steroids (dose ?  mg/day of methylprednisolone or equivalent)
Glucocorticoid therapy (prednisone >  mg/day or equivalent) within  days prior to randomization
Use of systemic steroids at an equivalent dose of prednisone  mg/day or higher within  weeks of day  of protocol therapy
Glucocorticoid therapy (prednisone >  mg/day or equivalent) within the last three weeks
Low-dose corticosteroids (prednisone < mg/ day or equivalent dose) are permitted throughout study.
High-dose corticosteroids (prednisone ?mg/day or equivalent dose) must be discontinued ?  days of initiating therapy.
Subject has received a cumulative dose of corticosteroids more than the equivalent of >=  mg of prednisone within the week period before cycle , day 
Glucocorticoid therapy (prednisone >  mg/day or equivalent) within  days prior to randomization.
Glucocorticoid use, unless given in doses less than or equal to mg/Day prednisone (or equivalent) for less than  Days for exacerbations other than CLL (e.g. asthma).*
Regular treatment with corticosteroids within the  weeks prior to the start of Cycle , unless administered for indications other than NHL at a dose equivalent to <  mg/day prednisone/prednisolone
Patients receiving high dose opioids on a chronic basis (greater than or equivalent to  mg of morphine per day)
Ongoing treatment with corticosteroids with a dose > milligram (mg) prednisone or equivalent per day at the time of randomization; or > mg cumulative prednisone dose or equivalent for any -week period in the year prior to randomization
Treatment with systemic immune modulators including, but not limited to, nontopical systemic corticosteroids (unless the dose is ?  mg/day prednisone or equivalent), cyclosporine, and tacrolimus within  weeks before study day 
Subjects with a condition with anticipated use of systemic steroids above the equivalent of  mg prednisone are excluded.
Corticosteroids are allowed, but must be dosed at prednisone  mg (or equivalent) or lower prior to the start of chemotherapy